ArchPoint Investors Purchases Shares of 121,400 Climb Bio, Inc. $CLYM

ArchPoint Investors acquired a new stake in shares of Climb Bio, Inc. (NASDAQ:CLYM) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 121,400 shares of the company’s stock, valued at approximately $486,000. ArchPoint Investors owned 0.18% of Climb Bio as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the stock. Barclays PLC boosted its stake in shares of Climb Bio by 149.9% during the fourth quarter. Barclays PLC now owns 61,853 shares of the company’s stock valued at $247,000 after purchasing an additional 37,100 shares during the period. Marshall Wace LLP lifted its stake in Climb Bio by 32.2% in the fourth quarter. Marshall Wace LLP now owns 304,015 shares of the company’s stock worth $1,216,000 after acquiring an additional 74,126 shares during the period. The Manufacturers Life Insurance Company lifted its stake in Climb Bio by 261.5% in the fourth quarter. The Manufacturers Life Insurance Company now owns 140,617 shares of the company’s stock worth $567,000 after acquiring an additional 101,717 shares during the period. Hudson Bay Capital Management LP purchased a new stake in Climb Bio in the fourth quarter worth $195,000. Finally, State Street Corp lifted its stake in Climb Bio by 25.0% in the fourth quarter. State Street Corp now owns 128,900 shares of the company’s stock worth $516,000 after acquiring an additional 25,800 shares during the period. Hedge funds and other institutional investors own 69.76% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on CLYM shares. Wedbush reissued an “outperform” rating and set a $17.00 price objective on shares of Climb Bio in a research report on Friday. BTIG Research raised their price target on Climb Bio from $19.00 to $20.00 and gave the company a “buy” rating in a report on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Climb Bio in a report on Monday, April 20th. Chardan Capital initiated coverage on Climb Bio in a report on Tuesday, May 5th. They set a “buy” rating and a $22.00 price target for the company. Finally, Oppenheimer raised their price target on Climb Bio from $10.00 to $18.00 and gave the company an “outperform” rating in a report on Tuesday, April 21st. Three investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Climb Bio currently has an average rating of “Buy” and a consensus target price of $21.73.

Climb Bio Stock Performance

NASDAQ CLYM opened at $11.44 on Friday. Climb Bio, Inc. has a one year low of $1.16 and a one year high of $12.48. The stock has a 50-day moving average of $9.96 and a 200 day moving average of $6.70. The company has a market capitalization of $655.05 million, a price-to-earnings ratio of -14.67 and a beta of 0.09.

Climb Bio (NASDAQ:CLYM) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.06. On average, equities analysts predict that Climb Bio, Inc. will post -0.87 earnings per share for the current fiscal year.

Climb Bio Company Profile

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.